Polyrizon Ltd. has announced a strategic initiative to explore selective investments in revenue-generating assets, focusing on companies operating in high-potential sectors such as defense, aviation, and artificial intelligence. The company aims to utilize its strong cash position and debt-free balance sheet to generate near-term revenues, enhance financial stability, and create additional shareholder value. While pursuing these opportunities, Polyrizon will continue to prioritize the advancement of its core intranasal medical device pipeline, including ongoing product development, preclinical and clinical studies, and regulatory progress for products such as PL-14, PL-16, and the Trap & Target platform.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9624746-en) on January 13, 2026, and is solely responsible for the information contained therein.